A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Administering Multiple Oral Doses of GSK1292263 Alone and With Atorvastatin
Public ClinicalTrials.gov record NCT01218204. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Study identification
- NCT ID
- NCT01218204
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- GlaxoSmithKline
- Industry
- Enrollment
- 287 participants
Conditions and interventions
Conditions
Interventions
- 100mg GSK1292263 Drug
- 10mg atorvastatin Drug
- 10mg ezetimibe Drug
- 300mg GSK1292263 Drug
- 800mg GSK1292263 Drug
- 80mg atorvastatin Drug
- GSK1292263 Placebo Drug
- Washout Other
Drug · Other
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 13, 2010
- Primary completion
- Jun 28, 2011
- Completion
- Jun 28, 2011
- Last update posted
- Jul 15, 2019
2010 – 2011
United States locations
- U.S. sites
- 21
- U.S. states
- 14
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| GSK Investigational Site | Anniston | Alabama | 36207 | — |
| GSK Investigational Site | Chula Vista | California | 91910 | — |
| GSK Investigational Site | Stockton | California | 95204 | — |
| GSK Investigational Site | Jacksonville | Florida | 32216 | — |
| GSK Investigational Site | Miami | Florida | 33169 | — |
| GSK Investigational Site | Miami | Florida | 33183 | — |
| GSK Investigational Site | Port Orange | Florida | 32127 | — |
| GSK Investigational Site | St. Petersburg | Florida | 33709 | — |
| GSK Investigational Site | Chicago | Illinois | 60607 | — |
| GSK Investigational Site | Chicago | Illinois | 60610 | — |
| GSK Investigational Site | Louisville | Kentucky | 40213 | — |
| GSK Investigational Site | Kalamazoo | Michigan | 49007 | — |
| GSK Investigational Site | Minneapolis | Minnesota | 55430 | — |
| GSK Investigational Site | Berlin | New Jersey | 08009 | — |
| GSK Investigational Site | Cincinnati | Ohio | 45246 | — |
| GSK Investigational Site | Oklahoma City | Oklahoma | 73112 | — |
| GSK Investigational Site | Eugene | Oregon | 97404 | — |
| GSK Investigational Site | Spartanburg | South Carolina | 29303 | — |
| GSK Investigational Site | San Antonio | Texas | 78205 | — |
| GSK Investigational Site | San Antonio | Texas | 78229 | — |
| GSK Investigational Site | Renton | Washington | 98057 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01218204, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 15, 2019 · Synced May 11, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01218204 live on ClinicalTrials.gov.